Lindsay Howard
Family · Florence, SCNPI 1720289135
Payments from drug & device makers
Across 340 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$601
- Lilly USA, LLC$378
- GSK$366
- Amgen$357
- Novo Nordisk$333
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,554100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 78 | $1,192 |
| AstraZeneca | 34 | $601 |
| Lilly USA, LLC | 30 | $378 |
| GSK | 19 | $366 |
| Amgen(2 entities) | 21 | $357 |
| Novo Nordisk | 21 | $333 |
| Abbott | 18 | $275 |
| Boehringer Ingelheim | 12 | $184 |
| Bayer | 9 | $172 |
| Pfizer | 11 | $168 |
| Esperion Therapeutics, Inc. | 9 | $135 |
| Sanofi-aventis U.S. LLC | 8 | $131 |
| Novartis | 8 | $130 |
| Relievant Medsystems, Inc. | 1 | $125 |
| Amarin Pharma, Inc. | 7 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $96 |
| Biohaven Pharmaceuticals, Inc. | 5 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $89 |
| Merck | 5 | $73 |
| Idorsia Pharmaceuticals US Inc | 5 | $71 |
| Kowa Pharmaceuticals America, Inc. | 4 | $61 |
| Seqirus USA Inc | 3 | $59 |
| Shield Therapeutics Inc | 3 | $53 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Exact Sciences | 2 | $35 |
| United Therapeutics Corporation | 1 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Eisai Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Johnson & Johnson | 1 | $19 |
| Nevro Corp. | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$499
How this compares
$5,554 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 90 | $107,108 |
| OzempicSemaglutide | 64 | $77,996 |
| JardianceEmpagliflozin | 61 | $57,076 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $55,462 |
| EliquisApixaban | 69 | $52,258 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $23,676 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $22,253 |
| XareltoRivaroxaban | 29 | $20,830 |
| JanuviaSitagliptin Phosphate | 25 | $19,811 |
| FarxigaDapagliflozin Propanediol | 21 | $16,274 |
| Repatha SureclickEvolocumab | 22 | $15,671 |
| KerendiaFinerenone | 17 | $15,335 |
| SynthroidLevothyroxine Sodium | 141 | $9,727 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $8,659 |
| PremarinEstrogens, Conjugated | 18 | $8,321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $378 | $107,10890 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $366 | $84,755111 claims |
| Novo NordiskOzempic | $333 | $77,99664 claims |
| PfizerEliquis, Premarin | $168 | $60,58087 claims |
| Boehringer IngelheimJardiance | $184 | $57,07661 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $601 | $44,34258 claims |
| Johnson & JohnsonXarelto | $19 | $20,83029 claims |
| MerckJanuvia | $73 | $19,81125 claims |
| BayerKerendia | $172 | $15,33517 claims |
| AbbVieSynthroid | $1,192 | $9,727141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.
Other family in Florence
- Sharon WaltersFlorence$19K
- Pansi PatelFlorence$13K
- Elizabeth WoodberryFlorence$10K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.